Anti-angiogenesis approach to genitourinary cancer treatment

Update on Cancer Therapeutics

Volumn 3, Issue 4, 2009, Pages 182-188

  Aragon Ching, Jeanny B ^a   Dahut, William L ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Bladder cancer; Prostate cancer; Renal cell cancer; Sorafenib; Sunitinib

Indexed keywords

ALPHA INTERFERON A; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CISPLATIN; DOCETAXEL; ESTRAMUSTINE; GEMCITABINE; GROWTH FACTOR; INTERLEUKIN 2; PLACEBO; PREDNISONE; SEMAXANIB; SORAFENIB; SUNITINIB; SURAMIN; THALIDOMIDE; VASCULOTROPIN A;

ADD ON THERAPY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BIOLOGY; BLADDER CANCER; CANCER THERAPY; CELL ADHESION; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; HYPOXIA; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

EID: 67651087280     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2009.05.002     Document Type: Review

References (89)

1. Hall A. The role of angiogenesis in cancer. Comp Clin Path 13 (2005) 95-99
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
3. Folkman J. History of angiogenesis. In: Figg W., and Folkman J. (Eds). Angiogenesis: an integrative approach from science to medicine (2008), Springer Science, New York, NY 1-14
4. FDA Approval Summary for Bevacizumab - National Cancer Institute. Accessed on: November 10, 2008. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab.
5. Epstein R.J. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev (2007)
6. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67 (1995) 281-316
7. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312 (2006) 549-560
8. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
9. Ferrara N., and Gerber H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 106 (2001) 148-156
10. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002) 795-803
11. Galland F., Karamysheva A., Pebusque M.J., Borg J.P., Rottapel R., Dubreuil P., et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8 (1993) 1233-1240
12. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15 (1996) 1751
13. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., and Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6 (1991) 1677-1683
14. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
15. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
16. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5 (1999) 495-502
17. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (2002) 4368-4380
18. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281 (2006) 951-961
19. Iruela-Arispe M.L. Endothelial cell activation. In: Figg W., and Folkman J. (Eds). Angiogenesis: an integrative approach from science to medicine (2008), Springer Science, New York, NY 35-43
20. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
21. Francis S.E., Goh K.L., Hodivala-Dilke K., Bader B.L., Stark M., Davidson D., et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 22 (2002) 927-933
22. Stupp R., and Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 25 (2007) 1637-1638
23. Wang G.L., and Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268 (1993) 21513-21518
24. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270 (1995) 1230-1237
25. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356 (2007) 185-187
26. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
27. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
28. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91 (1994) 9700-9704
29. Murdoch C., Giannoudis A., and Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104 (2004) 2224-2234
30. Gunningham S.P., Currie M.J., Han C., Turner K., Scott P.A., Robinson B.A., et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61 (2001) 3206-3211
31. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
32. Bochner B.H., Cote R.J., Weidner N., Groshen S., Chen S.C., Skinner D.G., et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87 (1995) 1603-1612
33. Jaeger T.M., Weidner N., Chew K., Moore D.H., Kerschmann R.L., Waldman F.M., et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154 (1995) 69-71
34. Gettman M.T., Pacelli A., Slezak J., Bergstralh E.J., Blute M., Zincke H., et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 54 (1999) 479-485
35. Figg W.D., Arlen P., Gulley J., Fernandez P., Noone M., Fedenko K., et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28 (2001) 62-66
36. Figg W.D., Dahut W., Duray P., Hamilton M., Tompkins A., Steinberg S.M., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
37. Figg W.D., Kruger E.A., Price D.K., Kim S., and Dahut W.D. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 20 (2002) 183-194
38. Figg W.D., Li H., Sissung T., Retter A., Wu S., Gulley J.L., et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 99 (2007) 1047-1055
39. Dahut W.L., Gulley J.L., Arlen P.M., Liu Y., Fedenko K.M., Steinberg S.M., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
40. Bok R.A., Halabi S., Fei D.T., Rodriquez C.R., Hayes D.F., Vogelzang N.J., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61 (2001) 2533-2536
41. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
42. Slaton J.W., Millikan R., Inoue K., Karashima T., Czerniak B., Shen Y., et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 171 (2004) 570-574
43. Black P.C., Agarwal P.K., and Dinney C.P. Targeted therapies in bladder cancer-an update. Urol Oncol 25 (2007) 433-438
44. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
45. Srinivasan R., Armstrong A.J., Dahut W., and George D.J. Anti-angiogenic therapy in renal cell cancer. BJU Int 99 (2007) 1296-1300
46. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
47. Sonpavde G. Bevacizumab in renal-cell cancer. N Engl J Med 349 (2003) 1674
48. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
49. Sternberg C.N. Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nat Clin Pract Urol 5 (2008) 422-423
50. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Ou S.S., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422-5428
51. Reese D.M., Fratesi P., Corry M., Novotny W., Holmgren E., and Small E. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 3 (2001) 65-70
52. Picus J. Docetaxel/bevacizumab (Avastin) in prostate cancer [abstract]. Cancer Invest 22 60 (2004) No. 46
53. CALGB 90401. Docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy. Accessed on: September 22, 2007. http://clinicaltrials.gov/ct/show/NCT00110214.
54. Figg W.D., Retter A., Steinberg S.M., and Dahut W.L. In reply. J Clin Oncol 23 (2005) 2113-a-2114
55. Ning Y.M., Arlen P.M., Gulley J.L., Stein W.D., Fojo A.T., Latham L., et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol (Meeting Abstracts) 26 (2008) 5000
56. NCT00234494: Cisplatin, Gemcitabine and Bevacizumab in combination for metastatic transitional cell cancer. Accessed on: November 9, 2008. http://clinicaltrials.gov/ct2/show/NCT00234494.
57. Wilhelm S. Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 8 (2002) 2255-2257
58. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
59. FDA Approval Summary for Sorafenib Tosylate - National Cancer Institute. Accessed on: November 10, 2008. http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate.
60. Hutson T.E., Figlin R.A., Kuhn J.G., and Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13 (2008) 1084-1096
61. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
62. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
63. Chi K.N., Ellard S.L., Hotte S.J., Czaykowski P., Moore M., Ruether J.D., et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007)
64. Steinbild S., Mross K., Frost A., Morant R., Gillessen S., Dittrich C., et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97 (2007) 1480-1485
65. Dahut W.L., Scripture C., Posadas E., Jain L., Gulley J.L., Arlen P.M., et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14 (2008) 209-214
66. NCT00414388. Sorafenib to overcome resistance to systemic chemotherapy in androgen-independent prostate cancer. Accessed on: September 22, 2007. http://clinicaltrials.gov/show/NCT00414388.
67. Dreicer R., Li H., Stein M.N., DiPaola R.P., Eleff M., Roth B.J., et al. Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (Meeting Abstracts) 26 (2008) 5083
68. Sridhar SS, Winquist E, Eisen A, Hotte SJ, Elaine M, Mukherjee SD, et al. A phase II study of first-line sorafenib (Bay 43-9006) in advanced or metastatic urothelial cancer. A trial of the PMH Phase II Consortium, 2008 Genitourinary Cancers Symposium. San Francisco, CA, 2008.
69. NCT00461851. Trial of gemcitabine, carboplatin, and sorafenib in chemotherapy-naive patients with advanced/metastatic bladder carcinoma. Accessed on: November 15, 2008. http://clinicaltrials.gov/ct2/show/NCT00461851?term=gemzar&rank=45.
70. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 (2007) 884-896
71. Christensen J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18 Suppl 10 (2007) x3-x10
72. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
73. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
74. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
75. Motzer R.J., and Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 370 (2007) 2071-2073
76. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
77. Figlin R.A., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Negrier S., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 26 (2008) 5024
78. NCT00137436. Study of SU011248 in combination with docetaxel (taxotere.) and prednisone in patients with prostate cancer. Accessed on: September 22, 2007. http://clinicaltrials.gov/show/NCT00137436.
79. Cooney M.M., Garcia J.A., Elson P., Mekhail T., Dreicer R., Nock C.J., et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial. J Clin Oncol (Meeting Abstracts) 26 (2008) 3530-
80. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
81. Takeda M., Arao T., Yokote H., Komatsu T., Yanagihara K., Sasaki H., et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 13 (2007) 3051-3057
82. Sridhar S.S., Mackenzie M.J., Hotte S.J., Mukherjee S.D., Kollmannsberger C., Haider M.A., et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol (Meeting Abstracts) 26 (2008) 5047
83. Karakunnel J.J., Gulley J.L., Arlen P.M., Mulquin M., Wright J.J., Turkbey I.B., et al. Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 26 (2008) 5136
84. Ryan C.J., Stadler W.M., Roth B., Hutcheon D., Conry S., Puchalski T., et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25 (2007) 445-451
85. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159
86. Ng S.S., and Chi K.N. Surrogates for clinical development. In: Figg W., and Folkman J. (Eds). Angiogenesis: an integrative approach from science to medicine (2008), Springer Science, New York, NY 313-320
87. De Bazelaire C., Rofsky N.M., Duhamel G., Michaelson M.D., George D., and Alsop D.C. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad Radiol 12 (2005) 347-357
88. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
89. Hahn O.M., Yang C., Medved M., Karczmar G., Kistner E., Karrison T., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26 (2008) 4572-4578